Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

Susan Bernstein  |  Issue: March 2020  |  February 25, 2020

In a review published in 2019, Dr. James’ laboratory collaborated with rheumatology researchers from the University of Colorado to compare elevations of soluble mediators that precede both clinical SLE and rheumatoid arthritis (RA) in patient cohorts from the U.S. military. Within one to two years before patients meet the classification criteria for RA, certain cytokines and chemokines, including IL-6, IFN-c and TNF-b, dramatically increase. In lupus, cytokines and chemokines elevate within the final year before classification, with BLyS ramping up very close to diagnosis, she said.7

Risk Influencers
Research teams are using very large patient cohorts, such as the Nurses’ Health Study I and II, and the Black Women’s Health Study, to identify epidemiological factors, including age at menarche, smoking status, obesity and alcohol use, that may influence lupus risk. Nurses’ Health Study data were used to show that moderate drinking is somewhat protective when it comes to lupus risk in women, and depression is associated with elevated SLE risk.8,9

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Relatives of SLE patients often ask Dr. James about their risk of developing lupus or other autoimmune diseases. She and her colleagues studied patients and first-degree relatives of people with SLE and RA in a study published in 2019.10 They examined serum samples from family members to look for disease-specific autoantibodies and tested samples for antibodies against thyroid disease, celiac disease and type-1 diabetes. The study grouped patients as having alternative autoantibodies if they had at least one autoantibody not associated with their relative’s autoimmune disease and having expanded autoimmunity if they had autoantibodies associated with two or more different diseases.

SLE patients’ relatives were more likely than RA patients’ relatives to have either alternative or expanded autoimmunity. Alternative autoimmunity was primarily systemic in the SLE cohort, while it was organ-specific in families of patients with type-1 diabetes. People in the RA cohort were more likely to have both systemic and organ-specific alternative autoimmunity, and they had mostly anti-TPO antibodies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In a follow-up study, Dr. James and her collaborators studied blood samples from lupus patients’ relatives to look for factors that may indicate which autoantibody-positive relatives had the highest risk of transitioning to lupus. They identified 45 relatives of lupus patients from lupus genetics studies who had transitioned to having four or more ACR SLE classification criteria during a mean follow-up period of 6.4 years; 73.8% were European American, 14.7% were African American, 2.5% were Hispanic and 9% were from other ethnic backgrounds, including Native Americans. European Americans had the lowest transition rate, 0.81 transitions per 100 follow-up years, while African Americans had 1.45 transitions and Native Americans had 2.27 transitions.11

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:2019 ACR/ARP Annual Meetingenvironmental factorgeneticSLEsystemic lupus erythematosus (SLE)

Related Articles

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

    A Team Approach Improves the Transition from Pediatric to Adult Care

    April 17, 2021

    Nearly all adolescents and young adults (AYAs) with chronic pediatric rheumatic disease require transfer of care to an adult rheumatologist, yet almost half are lost from care at the time of transfer.1-3 Although sometimes framed as a discrete event, transition refers to the longitudinal process, often spanning several years, in which AYAs and their families…

    Know Your Labs

    February 1, 2009

    A review of state-of-the-art testing for SLE and connective tissue disease.

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences